Merck Life Science is seeking applications from emerging biopharmaceutical and biotechnology start-ups in Australia and New Zealand for its Advance Biotech Grant Program.
The grant program is offered regularly in different regions of the world. It recognises stand-out emerging companies and awards grant recipients with products, services, and consultation to advance production and help accelerate the path to commercialisation.
Companies can submit applications describing their therapeutic focus and clinical strategy and explain how the program can help overcome challenges and address gaps in expertise.
The total grant pool available is $175,600.
The grand prize grant for Australia and New Zealand includes $136,000 in product and service support, such as upstream, downstream, and formulation consultation services, and a subscription to the Emprove Premium program.
Up to two finalists will be awarded prizes worth $19,800, which they can use to purchase biopharmaceutical processing technologies and/or technical process consultations.
The 2024 Australia and New Zealand Advance Biotech Grant Program application cycle is open. Click here to submit an application.
